SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will webcast three upcoming investor events.

First, Gen-Probe will release its third quarter 2008 financial results on Thursday, October 30, 2008 at approximately 4:00 pm Eastern Time (ET), followed by a conference call with management at 4:30 pm ET. The conference call will be webcast live and may be accessed on the investors section of the Company's web site at http://www.gen-probe.com. An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 866-505-9257 (US) or 203-369-1881 (international).

Second, the Company will present at Oppenheimer's 19th Annual Healthcare Conference in New York on Tuesday, November 4, 2008 at 12:40 pm ET. The presentation is scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website. The webcast will be available for 30 days following the event.

Third, Gen-Probe will webcast its annual meeting with institutional investors and sell-side analysts in San Diego on Friday, November 7, 2008, at 8 am Pacific Time (11 am ET). The meeting, which will feature presentations on Gen-Probe's current business and future growth strategies, will conclude at approximately 11 am Pacific Time (2 pm ET). Institutional investors and sell-side analysts can RSVP to attend in person by contacting Paula Izidoro at paulai@gen-probe.com. Please note the new date and time. Others may access a live webcast through a link on the investors section of Gen-Probe's website. The webcast will be available for 30 days following the event.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended June 30, 2008, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact:
Paula Izidoro
Investor Relations
858-410-8904

SOURCE Gen-Probe Incorporated